Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892384 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01892384 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 40 participants.
The verdict
NCT01892384, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days. A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 409306 in schizophrenic patients.
Interventions
- DRUG Placebo
- DRUG BI 409306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-06-28 |
| Est. Completion | 2013-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01892384
The ClinicalTrials.gov registry entry for NCT01892384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01892384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01892384 about?
NCT01892384 is a clinical study titled "Safety and Tolerability of BI 409306 in Patients With Schizophrenia". The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days. A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics o...
What is the current status of trial NCT01892384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-06-28. Estimated completion is 2013-12-05.
What interventions are being tested in trial NCT01892384?
The interventions under investigation include: Placebo (DRUG), BI 409306 (DRUG).
Who is sponsoring clinical trial NCT01892384?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.